Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 32 resultados

PrIMAVeRa: Predicting the Impact of Monoclonal Antibodies Vaccines on Antimicrobial Resistance GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-speci...
2021-11-09 - 2026-10-31 | Financiado

Inno4Vac: Innovations to accelerate vaccine development and manufacture GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado

PROMISE: Preparing for RSV Immunisation and Surveillance in Europe GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado

Vacc-iNTS: Advancing a GMMA based vaccine against invasive non typhoidal salmonellosis through Phase 1 trial in... Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan A...
2019-04-30 - 2026-07-31 | Financiado

VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado

COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado

DRIVE: Development of Robust and Innovative Vaccine Effectiveness GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the...
2017-08-08 - 2022-06-30 | Financiado

RESCEU: REspiratory Syncytial virus Consortium in EUrope Sofia ref. 116019 GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk gr...
2016-12-14 - 2022-09-30 | Financiado

PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado

VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado

DiViNe: Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies novel a... GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-BIOTEC-2014-2015 In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any cont...
2015-02-11 - 2020-02-29 | Financiado

EbolaVac: Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine GLAXOSMITHKLINE BIOLOGICALS SA tramitó un H2020: DIGITAL-2024-CLOUD-AI-06 The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organizatio...
2014-12-09 - 2018-04-06 | Financiado

TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... GLAXOSMITHKLINE BIOLOGICALS SA participó en un H2020: H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado

FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado

ADVANCE: Accelerated Development of Vaccine benefit-risk Collaboration in Europe GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6: Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to...
2013-10-01 - 2019-03-31 | Financiado

BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety GLAXOSMITHKLINE BIOLOGICALS SA participó en un FP6: BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado

ADJSYN: Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7: The need to develop vaccines against challenging diseases such as malaria or tuberculosis requires effective adjuvants to improve the immune...
Financiado

SIMULATA: System for Immunological Modelling as an Ultimate tool to Link Adjuvant function To Adaptive immune... GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7: The aim of the proposal is to construct an in vitro model of human cellular immune responses and to address fundamental questions on the lin...
Financiado

T-BAC: Exploring the roles and plasticity of T cell responses in anti BACterial immunity GLAXOSMITHKLINE BIOLOGICALS SA tramitó un FP7: "Antibodies against bacterial polysaccharides and proteins play a role in anti-bacterial immunity. To date, S. aureus vaccine candidates wer...
Financiado

GSKBIO